DigiPath Labs Provides Insight on Proposed Puerto Rico Medical Cannabis Law

Warning message

The subscription service is currently unavailable. Please try again later.

DigiPath Labs Provides Insight on Proposed Puerto Rico Medical Cannabis Law

DigiPath Labs, the cannabis testing subsidiary of DigiPath, Inc. (OTCQB: DIGP), recently expressed concerns that Puerto Rico's new state-run medical cannabis policy does not include third-party safety testing, a crucial assurance to patients that their medicine is safe. In an interview with Caribbean Business journal, DigiPath Labs Chief Science Officer Cindy Orser, PhD, explains the need for consistent standards in cannabis testing and notes that the proposed Puerto Rican medical cannabis law, in its current form, fails to embrace the requirement for independent quality assurance.

Under a draft of the law released on July 21, the Department of Public Health would oversee Puerto Rico's medical cannabis program, running all dispensaries, with the University of Puerto Rico growing all cannabis.  The draft law has no provisions for quality assurance testing of the resulting product....

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.